The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder.
J Neuroimmunol
; 328: 1-4, 2019 03 15.
Article
em En
| MEDLINE
| ID: mdl-30543869
ABSTRACT
In neuromyelitis optica spectrum disorders (NMOSD), the clinical and long-term prognostic value of antinuclear antibodies (ANAs) is unclear. We analyzed registry data of NMO-IgG seropositive NMOSD patients (nâ¯=â¯74) according to ANA presence. The ANA-positive group (nâ¯=â¯32) demonstrated more frequent other autoantibodies (anti-SSA/Ro, anti-SSB/La, antiphospholipid, and anti-double stranded DNA antibodies) than did the ANA-negative group (nâ¯=â¯42). Clinically, annual relapse rates, and average lesion extents on MRI during attacks were comparable between the two groups (median follow-up of 7â¯years). The development of a poor outcome (walking with unilateral aid) also did not differ. In conclusion, although common, ANAs were not associated with a benign/malignant disease course in our NMOSD cohort.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Antinucleares
/
Neuromielite Óptica
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Neuroimmunol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Coréia do Sul